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Abstract
Chronic infection with the hepatitis delta virus (HDV) is a risk factor for cirrhosis and hepatocellular carcinoma (HCC), but
little is known whether the outcome of hepatitis is predicted by serum markers of HDV and hepatitis B virus (HBV) infection.
The aim of the study was to investigate these correlations in 193 patients with chronic HDV infection who had been
followed up for a median of 9.5 years (4.8–19.3). HDV-RNA was first measured by qualitative in-house nested RT-PCR and
quantified by in-house real-time PCR. HDV RNA levels only appeared significantly associated to HCC (univariate analysis: OR
1.32, 95% CI 1.02–1.71; p = 0.037; multivariate analysis: OR 1.42, 95% CI 1.04–1.95; p = 0.03). In non-cirrhotics at first
presentation (n = 105), HDV RNA levels were associated with progression to cirrhosis (univariate analysis: OR = 1.57, 95% CI
1.20–2.05, p,0.001; multivariate analysis: OR = 1.60, 95% CI 1.20–2.12, p = 0.007) and development of HCC (univariate
analysis: OR = 1.66, 95% CI 1.04–2.65, p = 0.033; multivariate analysis: OR = 1.88, 95% CI 1.11–3.19, p = 0.019). ROC analysis
showed that approximately 600,000 HDV RNA copies/mL was the optimal cut-off value in our cohort of patients for
discriminating the development of cirrhosis. High levels of HDV viremia in non-cirrhotic patients are associated with a
considerable likelihood of progression to cirrhosis and the development of HCC. Once cirrhosis has developed, the role of
HDV replication as a predictor of a negative outcome lessens.
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Introduction
Hepatitis delta virus (HDV) is a unique agent characterised by a
single-stranded RNA genome encapsidated by the hepatitis B
surface antigen (HBsAg) and a peculiar strategy of infection of the
target organ [1]. In fact, HDV requires the helper functions
provided by hepatitis B virus (HBV) in order to propagate to
hepatocytes, it can only infect subjects with co-existing HBV
infection due either to the simultaneous transmission of the two
viruses or superinfection in an established HBV carrier [2,3]. Not
surprisingly therefore, the incidence of HDV infection declined
rapidly in Southern Europe and the Mediterranean basin after the
early 1990s following the introduction of HBV vaccinations [4],
but the many immigrants from highly endemic areas carrying
chronic HDV infection has led to the emergence of a new scenario
in Western Europe as a whole [5–7].
Chronic HDV infection has always been considered severe and
rapidly progressive, leading to end-stage liver disease in just a few
years, whereas a more slowly progressive form has been identified
which evolved into cirrhosis in 30% of the patients followed up for
periods of up to 28 years, with liver decompensation rather than
liver cancer (HCC) being the first cirrhosis-related complication to
appear [8]. These observations suggest the existence of patient
populations with heterogeneously evolving forms of chronic HDV
infection, but the pathogenesis of HDV-related liver damage is still
controversial. It seems unlikely that the virus has a direct
cytopathic effect because studies have found liver grafts expressing
HDAg alone without any tissue injury [9]. On the other hand, the
so-called replication-associated cytopathogenicity of the virus
might explain the tissue damage observed in patients with acute
HDV infection, which is characterised by high levels of viral
replication, whereas chronic infection is characterised by low levels
of viral production and pathogenicity [2,10]. Furthermore, recent
findings indicating the existence of a direct correlation between
serum levels of HBsAg and HDV RNA in the absence of an
inverse correlation with HBV DNA levels suggests an alternative
interpretation of HDV pathogenicity that is more closely related to
HBV biology [11].
The aim of this study was to investigate the correlations between
viremia (serum HBsAg, HBV DNA and HDV RNA levels) and
the clinical outcomes of chronic HDV infection, including the
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progression to cirrhosis, the development of HCC, decompensa-
tion, and liver-related death.
Patients and Methods
Patients
Patients were selected from the previously published cohort
attending the Liver Centre of Ospedale Maggiore in Milan (Italy)
[8]. The only selection criteria was the availability of multiple
frozen serum samples (270uC) collected at first visit at our division
(baseline sample), as well as at least one frozen sample collected
over follow-up. The study was approved by the Institutional
Review Board of the Department of Internal Medicine at
Maggiore Hospital. Patients gave their written informed consent
to take blood for experiments and gave permission for use of their
medical records.
Diagnosis of HDV Infection
HDV infection was defined as the presence of HDV antigen
(HDAg) in liver tissue, or the detection of serum HDV RNA in
anti-HDV/HBsAg seropositive patients as detailed elsewhere [12].
HDV RNA Extraction
HDV RNA was extracted from 200 mL of plasma using the
High Pure Viral Nucleic Acid kit (Roche Applied Science, Basel,
Switzerland). As many of the samples had very low concentrations
of HDV RNA, it was essential to ensure efficient viral nucleic acid
extraction. We therefore modified the extraction protocol includ-
ing a preliminary step of one hour’s incubation with the lysis/
binding buffer supplied with the kit (chaotropic salt, poly(A), and
proteinase K) at room temperature.
Quantitative HDV RNA Real-time PCR
An HDV RNA reference standard for the quantification of
HDV RNA by Real Time PCR is not currently available. A
569 bp fragment of the HDV genome including the 59 UTR HDV
region has been cloned into a plasmid, which was used as positive
control transcript for HDV Real Time PCR assay. Alignment of
full-length HDV GenBank reference genomes representative of all
HDV genotypes was used to locate conserved regions suitable for
HDV RNA amplification, and the 59 untranslated (UTR) region
was identified as the most appropriate, as defined by others [13].
Thus, primers and probes were designed to amplify a 110 bp
fragment of the 59 UTR, taking into account the genetic variability
of HDV genotypes. The assay was based on the use of fluorescence
resonance energy transfer (FRET) probes, and included the
forward primer HDV-s AGTGGCTCTCCCTTAGCCAT, the
reverse primer HDV-as CGTCCTTCTTTCCTCTTCGGGT,
the 39-fluorescein-labelled probe HDV-FL TCCTCCTTCGG-
ATGCCCAGGTCG, and the 59-LC640-labelled probe HDV-LC
CCGCGAGGAGGTGGAGATGCCAT. The reaction was per-
formed using a LightCycler 2.0 instrument (Roche Diagnostics)
and a 20 mL total volume containing 16LightCycler RNA Master
Hybridization Probe, 55 nM Mn(OAC)2, 10 mM of each primer
and probe, and 5 mL of RNA, and consisted of initial RNA
retrotranscription (and Taq activation) for 259 at 61uC followed by
300 at 95uC, and then 45 amplification cycles (10 at 95uC, 50 at
62uC, and 40 at 72uC) and a final melting curve analysis (300 at
72uC, 200 at 95uC, 300 at 40uC, 10 at 85uC, and 300 at 40uC). All
quantification were performed relatively to the plasmid standard
described, which was used to define the 4-point quantification
curve in each assay. Moreover, a real sample from the same
patient was introduced in each Reverse Transcription-Real Time
PCR analysis as positive internal control. The linearity of the PCR
ranged from 103 to 108 copies/mL, and the sensitivity was 500
copies/mL. All samples were tested in duplicate and the mean of
the two analysis was considered for statistical analysis. For the
validation of the assay, a subset of 50 samples were also tested with
a commercial CE IVD HVD Real Time PCR assay (LifeRiver
Diagnostics, Shanghai, China), with concordant results (data not
shown).
HBsAg Quantification
HBsAg was quantified by means of automated chemilumines-
cent microparticle immunoassays (Architect HBsAg, Abbott,
Chicago, IL).
HBV DNA Quantification
For the purposes of this study, all of the patients were re-tested
for HBV DNA by means of quantitative real-time PCR using a
COBAS AmpliPrep/COBAS TaqMan automated system (HBV
Test, Roche Diagnostics).
Liver Biopsy
Liver biopsies were obtained using a Tru-cut needle (16 gauge,
Travenol, Hyland, CA; Uro-Cut 16G, TSK, Tokyo, Japan), and
the sections were stained by means of conventional procedures.
Liver cell necrosis, inflammation and fibrosis were graded on the
basis of the METAVIR scoring system [14].
Disease Progression
Progression to cirrhosis in patients presenting with chronic
hepatitis at entry was defined on the basis of fibrosis at liver
histology (F 4) [14], a platelet count of ,100,000 mm3, the
ultrasound (US) features of surface nodularity, splenomegaly, a
portal vein diameter of .15 mm, endoscopically revealed
oesophageal varices.
In the patients presenting with cirrhosis at entry, disease
progression was defined as entry into a higher Child-Pugh class,
and the development of clinical decompensation or HCC [15].
All of the patients with a clinical or histological diagnosis of
cirrhosis underwent US surveillance and serum AFP determina-
tions every 6 months as previously described [16]. HCC was
diagnosed on the basis of the criteria used at the time of patient
evaluation; since 2001, we used the guidelines published by the
European Association for the Study of the Liver (EASL) [17]. In
patients undergoing echo-guided liver biopsy, HCC was classified
using internationally accepted criteria based on the pattern of
invasive or replacing growth [18]. Complications of cirrhosis other
than HCC, such as ascites, jaundice, hepatic encephalopathy and
GI bleeding, were diagnosed and treated in accordance with
established criteria [19,20].
Statistical Analysis
The categorical variables are given as numbers and percentages,
and the continuous variables as mean values6standard deviation
or median values and range, as appropriate. The serological
variables were log-transformed (base 10 logarithm) before analysis.
The chi-squared test and t test for independent samples were
respectively used to compare proportions and mean values. The
non parametric Mann–Whitney test was used in case of variables
with non normal distributions. Univariate logistic regression
models were used to assess the effect of the serological variables
at the time of presentation and the risk of developing an event of
interest (cirrhosis, HCC, liver decompensation, liver-related death,
and ‘‘at least one of these’’) during the follow-up. In addition,
multivariate logistic regression analyses were performed including
HDV RNA Levels as Predictors of Cirrhosis
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in the above described univariate models some potential relevant
confounders (age, sex, alcohol consumption, HBeAg and IFN).
Finally, a subgroup analysis was performed to assess the effect of
the variables of interest separately on the two subgroups of patients
defined according to the clinical diagnosis at baseline (chronic
hepatitis or cirrhosis). Odds ratios (ORs) with their 95%
confidence intervals were calculated for the variables included in
the models. In the logistic models, only patients with an available
serological determination before the development of the event
were included. A receiver operating characteristic (ROC) analysis
was used to asses the ability of log-transformed HDV RNA to
predict the development of cirrhosis in patients with chronic
hepatitis. The area under the curve (AUC) was calculated as an
overall assessment of the predictive ability of HDV RNA.
The sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) of the measurements were
calculated, and the optimal HDV RNA cut-off value for predicting
the development of cirrhosis was chosen on the basis of the
maximum Youden index (the sum of sensitivity and specificity
minus one). P values of ,0.05 (two-tailed) were considered
statistically significant. All of the statistical analyses were made
using SAS statistical software (release 9.2) (SAS Institute Inc.,
Cary, NC, USA).
Results
We selected 193 patients for whom a baseline serum sample was
available, as well as at least one sample collected over follow-up,
with a median of three (2–6) samples/patient. We were able to
select an homogeneous group of patients that reflected the original
population of 299 patients. Indeed, among the 193 cases selected
for the present study (65% of the original population), there were
35 patients who developed HCC (46 in the original cohort) and 35
who experienced liver decompensation (54 in the original cohort).
Table 1 shows the main epidemiological and virological
characteristics of the 193 patients at the time of study entry, i.e.
at the diagnosis of HDV infection, as compared to the general
cohort of 299 patients [8], that also included patients who were
diagnosed to have HDV infection in other institutions.,. The
patients were prevalently Italians (94%), males (76%) with a mean
age of 41 years. The modality of infection was sporadic in the vast
majority of cases (146/193, 76%), and 15 patients (8%) were
HBeAg positive. Thirty-eight cases (20%) had a previous history of
an alcohol intake of .40 g/day. HBsAg could be quantified in
187 cases (97%), and HBV DNA was detectable in 169 cases
(87%). All of the samples were HDV RNA positive upon
qualitative testing, and viremia could be quantified in 157 samples
(81%); the remaining 36 samples (19%) had concentrations that
were below the detection limit of the quantitative assay. Liver
cirrhosis was diagnosed at baseline in 88 cases (45%) by
histological criteria in 75 (85%) and clinical criteria in the
remaining 13 (15%). The proportion of cirrhosis was slightly
higher in the current cohort because we are a referral centre for
both HBV infection and advanced liver diseases. Therefore, we
often received from other Italian institutions patients with HBV
related cirrhosis before the diagnosis of HDV coinfection was
made. The clinical criteria for diagnosing cirrhosis were platelets
below 100.000 mm3 in all the 13 patients, the ultrasound (US)
features of surface nodularity in all patients, splenomegaly in eight,
a portal vein diameter of.15 mm in five, presence of oesophageal
varices in three. 82 (93%) patients were Child-Pugh class A, six
(7%) were Child-Pugh class B.
We were not able to evaluate differences between the two
cohorts in terms viral load, since baseline levels of HBsAg, HDV
RNA and HBV DNA could not be quantified in the general
cohort. Finally, in the original cohort, mean age and median
follow-up were calculated from the first evidence of chronic liver
disease, while in the current cohort, mean age and follow-up were
calculated at entry into the current study, corresponding to first
access to our unit, when the first serum sample was stored.
Table 2 shows the main characteristics of the patients with and
without liver cirrhosis. The patients with chronic hepatitis were
significantly younger than those with cirrhosis (37.3611.0 vs
44.9610.3, p,0.001), had different modalities of infection
(p = 0.024) and longer follow-up (p = 0.0003). There were no
differences in terms of gender, alcohol intake, or baseline levels of
HBsAg, HBV DNA or HDV RNA.
88 patients (45%) were previously treated with standard
Interferon at doses between 6 and 9 MU, for a median of 18
months (6–94). 51/88 had chronic hepatitis at baseline but 20 of
them progressed to cirrhosis over follow-up (histological diagnosis
in all cases), after a median treatment of 24 months (6–56). 33/88
had a virological response (i.e. persistently negative serum HDV
RNA or liver HDAg in at least 2-point analysis during 3 years of
follow-up,18 with chronic hepatitis). However, in spite of the
virological response, 5 chronic hepatitis progressed to cirrhosis
documented at liver histology.
Considering the occurrence of HCC, liver decompensation and
liver related death as clinical endpoints of the study, we performed
the univariate and multivariate analysis of the principal epidemi-
ological, clinical and virological variables. Among the 193 patients
at baseline, 28 (14.5%) developed HCC, 26 (13.5%) developed
liver decompensation and 25 (13%) died of liver related events. By
univariate analysis, the virological variables only emerged as
associated to the clinical outcome (Table 3). In particular, HDV
RNA levels appeared significantly associated to HCC develop-
ment (OR 1.32, 95% CI 1.02–1.71; p= 0.037) and occurrence of
at least one unfavourable event (i.e. HCC, liver decompensation,
liver related death) (OR 1.36, 95% CI 1.10–1.68; p = 0.004).
Levels of HBsAg were significantly associated to the occurrence of
liver decompensation (OR 2.31, 95% CI 1.09–4.91; p = 0.03).
However, by multivariate analysis, serum HDV RNA levels only
were confirmed as associated to HCC development (OR 1.42,
95% CI 1.04–1.95; p = 0.03) and occurrence of at least one
unfavourable outcome (OR 1.41, 95% CI 0.99–3.21; p = 0.007).
We also performed univariate and multivariate analysis
separately on patients with chronic hepatitis as well as in cirrhotic
patients. Among the 105 patients with chronic hepatitis at
baseline, 31 (29%) developed cirrhosis, 10 (9%) developed HCC,
7 (6%) developed liver decompensation and 7 (6%) died of liver
related events. The results of the univariate analyses of patients
with chronic hepatitis at baseline are summarised in Table 4.
Univariate analysis showed that the baseline HDV RNA levels of
the patients with chronic hepatitis were associated with progres-
sion to cirrhosis (OR=1.57, 95% CI 1.20–2.05, p,0.001) and the
development of HCC (OR=1.66, 95% CI 1.04–2.65, p = 0.033).
These findings were confirmed by the multivariate analysis
(cirrhosis: OR=1.56, 95% CI 1.14–2.12; p= 0.005; HCC:
OR=2.64, 95% CI 1.13–6.16; p= 0.025). Among the 88 patients
with cirrhosis at baseline, 25 (28%) developed HCC, 28 (32%)
developed liver decompensation and 28 (32%) died of liver related
death. Univariate analysis showed no association between the
serological parameters and the risk of any of the unfavourable
events. Finally, with a view to identifying levels of HDV viremia
correlated to a higher propensity of disease progression, we
performed the ROC analysis in patients with chronic hepatitis.
The ROC analysis identified 5.78 logHDV RNA (i.e. approxi-
mately 600,000 copies/mL) as the best cut-off value for predicting
HDV RNA Levels as Predictors of Cirrhosis
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the development of cirrhosis (AUC=0.73) in patients with chronic
hepatitis (Fig. 1). This value was calculated in our patient cohort
and with our HDV RNA quantification methods. This threshold
had a sensitivity of 74%, a specificity of 64%, a PPV of 46.9%, and
an NPV of 85.4%.
Table 1. Comparison of the main epidemiological and virological characteristics of the 193 patients (current cohort) and 299
patients (general cohort [8]) at study entry.
Current Cohort General Cohort
(n6=193) (n6=299) p
Italian origin, nu (%) 181 (94) 290 (97) ns
Males, nu (%) 147 (76) 230 (77) ns
Mean age, years 40.8 30.5 na
Modality of infection, nu (%)
Unknown 146 (76) 222 (74) ns
Post-transfusion 14 (7) 27 (9) ns
Intra venous drug use 24 (12) 38 (13) ns
Sexual activity 9 (5) 12 (4) ns
Alcohol .40 g/day, nu (%) 38 (20) 69 (23) ns
HBsAg quantified, nu (%) 187 (97) nd
HBeAg +, nu (%) 15 (8) 27 (9) ns
HDV-RNA positive, nu (%) 193 (100) 299 (100) ns
HDV-RNA .500 cp/mL, nu (%) 157 (81) nd
HBV DNA .50 IU/mL, nu (%) 169 (87) nd
Liver cirrhosis, nu (%) 88 (45) 104 (35) = 0.03*
Median follow-up, years 9.5 (4.8–19.3) 21 (1.2–43) na
nd =not done. In the general cohort [8] HBsAg, HDV RNA and HBV DNA were not quantified.
na = not applicable. In the original cohort [8], mean age and median follow-up were calculated from the first evidence of chronic liver disease. In the current cohort,
mean age and follow-up were calculated at entry into the current study, corresponding to first access to our unit as well as time of collection of the first serum sample
available for testing.
*The proportion of cirrhosis was slightly higher in the current cohort because we are a referral centre for both HBV infection and advanced liver diseases. Therefore, we
often received from other Italian institutions patients with HBV related cirrhosis before the diagnosis of HDV coinfection was made.
doi:10.1371/journal.pone.0092062.t001
Table 2. Main baseline epidemiological and virological characteristics of the patients with and without cirrhosis.
Chronic hepatitis Cirrhosis
(n=105) (n=88) p
Males, No. 83 (79%) 64 (73%) ns
Mean age 6 SD, years 37.3611.0 44.9610.3 ,0.001
Modality of infection, No. p = 0.0236
Unknown 71 (68%) 75 (85%)
Post-transfusion 9 (8%) 5 (6%)
Intra venous drug use 17 (16%) 7 (8%)
Sexual activity 8 (8%) 1 (1%)
Median follow-up, years 12.5 (6.6–19.9) 6.8 (3.8–16.5) p = 0.0003
Alcohol .40 g/day, No. 23 (22%) 15 (17%) ns
Mean log HBsAg 6 SD 3.460.8 3.660.6 ns
Mean log HBV-DNA 6 SD 3.061.6 3.061.4 ns
Mean log HDV-RNA 6 SD 5.061.9 5.261.6 ns
IFN treatment, No 51 (48%) 37 (42%) ns
Virological Response, No 18 (17%) 15 (17%) ns
doi:10.1371/journal.pone.0092062.t002
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Discussion
This study investigates a large cohort of patients followed up for
a median period of 9.5 years, selected from a wider cohort already
published [8]. The only criteria for selection was the availability of
multiple frozen serum samples collected at baseline as well as
during follow-up, in the respect of the overall characteristics of the
original population. The study provides novel insights into the role
and reciprocal interactions of HBV and HDV affecting the clinical
outcome of HDV-related chronic liver disease. As cirrhosis is the
major risk factor for late clinical complications, the non-cirrhotic
patients with histological signs of chronic hepatitis alone, and those
with histologically or clinically proven cirrhosis were analysed,
whereas the levels of HDV RNA, HBV DNA and HBsAg were
analysed in all of the samples collected at the time of clinical
presentation, as well as in the samples collected from patients at
the time of any subsequent development of cirrhosis or occurrence
of any major event like HCC, clinical decompensation and liver
related death.
The main finding of the study was that the clinical significance
of HDV viremia is different in patients with chronic hepatitis alone
and in those with established cirrhosis. Indeed, the univariate and
multivariate analyses showed that the level of HDV viremia was
the only virological parameter related to progression to cirrhosis
and the end-stage complications of HDV, including HCC and
clinical decompensation, in the patients who were not cirrhotic at
the time of clinical presentation. This is the first study showing that
the level of HDV viremia is the major driver of disease progression
in patients with chronic hepatitis D, although our results are in line
with previous findings that persistent HDV replication is the only
predictor of an adverse outcome in patients with hepatitis delta
[8]. Given the well-known inhibitory effect of HDV on HBV
replication [21,22], it is not surprising that most of the circulating
infectious viral particles contain HDV RNA instead of HBV DNA.
In a study of patients with HBV infection alone whose design was
similar to that of ours, Iloeje et al. found a close correlation
between progression to cirrhosis and the level of circulating virus
measured at the time of the first clinical observation, after
censoring for important comorbidity factors such as age, gender,
smoking and alcohol abuse [23].
Interestingly, we found similar baseline HDV RNA levels in our
cirrhotic and non-cirrhotic patients, which suggests that, in
addition to only predicting progression in the long term,
quantifying HDV viremia has no value in cross-sectional
evaluations. This hypothesis is supported by a recent cross-
sectional analysis of 80 patients from different countries that
showed no correlation between HDV RNA levels and histological
necro-inflammation and fibrosis scores [11].
Another interesting finding of our study is that, once cirrhosis
has developed, HDV RNA levels lose any significant relationship
with disease progression, i.e. the occurrence of HCC, decompen-
sation and liver related death. This finding may appear
controversial from our previous results. As a matter of fact, in
the previous publication we indicated that persistent HDV RNA
over time was a risk factor associated to the occurrence of clinical
decompensation, regardless from quantitative levels of HDV
RNA. We found differences in terms of median follow-up, having
chronic hepatitis patients significant longer observation time. One
possible explanation is that for each patient we considered the first
available sample as the baseline observation, regardless from the
first evidence of liver disease. A previous study [24] has found that
HDV viral replication tends to decline at the most advanced stages
of liver disease, whereas serum HBV DNA levels may increase
and, together with our data, this suggests that some factors not
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included in the present analysis, including comorbidities, lifestyles
and genetic predisposition, may influence the onset of complica-
tions in cirrhotic patients. This interpretation is supported by our
finding that serum HDV RNA is independently associated with
progression to cirrhosis and the development of HCC in patients
with chronic hepatitis alone.
When we analysed the serological variables against the risk of
developing at least one unfavourable event like progression to
cirrhosis, HCC, clinical decompensation or liver-related death in
these patients, there was a clear-cut trend towards a quantitative
relationship between viremia and the risk of liver complication. A
HDV RNA levels of .600,000 copies/mL predict in our cohort a
risk of cirrhosis in about 50% of patients with chronic hepatitis
(PPV=46.9%) whereas lower values are a useful means of
excluding the development of cirrhosis in a large number of cases
(NPV=85.4%). One possible explanation for higher levels of
HDV RNA being associated with a greater risk of disease
progression in patients with chronic hepatitis delta, is the influence
of virus replication on cell immune responses against HDV-
infected liver cells, as recently suggested by studies of host T cell
immune responses in hepatitis delta genotypes 1 and 2 [25,26].
The possibility that genetic diversity of HDV plays a role in
hepatitis progression is less likely since in our cohort of mainly
Italian patients (95%), HDV genotype 1 was the most prevalent
infecting strain [27].
While our findings clearly need to be validated in prospective
studies of larger patient populations, still they underline the
importance of treatment before cirrhosis occurs because, once it
has developed, our results indicate that there is no association
between any of the serological parameters and the occurrence of at
least one unfavourable event, like the development of HCC, liver
decompensation or liver-related death.T
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Figure 1. ROC analysis of HDV RNA levels. With a view to
identifying levels of HDV viremia correlated to a higher propensity of
disease progression, the ROC analysis identified 5.78 logHDV RNA (i.e.
approximately 600,000 copies/mL) as the best cut-off value for
predicting the development of cirrhosis (AUC=0.73) in patients with
chronic hepatitis.
doi:10.1371/journal.pone.0092062.g001
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We did not find any direct or indirect correlation between HDV
RNA and HBV DNA levels. As HDV proteins p24 and p27
repress the HBV enhancer by inhibiting HBV replication, and
HDV p27 transactivates the interferon alpha-inducible MxA gene,
which also inhibits HBV replication [28], it was no surprise to find
that most of our patients had no detectable HBV. The same was
found in long-term clinical study of potentially highly viremic
HBeAg positive patients with chronic hepatitis delta [29], which
demonstrated that most of the patients had HBV DNA levels of ,
200,000 IU/mL at least once during follow-up, and 60% had
levels of ,2,000 IU/mL. It has recently been found that HDV
patients carrying mutations at nucleotide positions 1762, 1764 and
1896 in the basal core promoter/precore region also have low
HBV levels [30].
Consistent with the epidemiology of HDV in the Mediterranean
basin, only 8% of the patients in our cohort were HBeAg positive
at baseline, and there was no significant correlation with clinical
outcome, as previously reported [29]. However, our findings and
those from Spain [31] conflict with a recent finding from Turkey
of the existence of a correlation between serum HBsAg levels and
HDV viremia, regardless of histological staging and the grading of
liver disease in patients with chronic hepatitis delta [11].
In conclusion, chronic hepatitis D is highly likely to progress to
cirrhosis and HCC in Italy, and this propensity is greater the
higher the level of HDV viremia at the time of presentation.
However, once cirrhosis has developed, the role of high HDV
levels as a predictor of a negative outcome becomes attenuated.
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